Beam Therapeutics Inc (BEAM) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Beam Therapeutics Inc   (NASDAQ: BEAM)


Beam Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Beam Therapeutics Inc's ROI in the second quarter of 2026?
Beam Therapeutics Inc recorded a cumulative net loss of $-85 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -6.54%.

Within the Healthcare sector 232 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 1827 to 2900.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 16.9 % 18.45 % 20.84 % 1.7 % -2.44 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 1,305 1,406 1,384 1,129 1,217
Return On Investment (TTM) -6.54 % -5.07 % -6.33 % -36.11 % -35.67 %
BEAM's Overall Ranking # 2900 # 1827 # 2289 # 3366 # 1489
Seq. Investment Change TTM 1.72 % 1.6 % 10.07 % 2.76 % 3.07 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -85 -65 -80 -415 -399

BEAM Company Profile >> Back to BEAM Roi Comparisons >> See Annual BEAM Return On Investment



Return On Investment BEAM's Ranking
Within: No.
Industry # 25
Sector # 233
Overall # 2900

Return On Investment Statistics
High Average Low
10.69 %
-13.56 %
-102.12 %
(March 31, 2012)   (Mar 31 2021)



  News about Beam Therapeutics Inc Return on Investment ROI

Beam Therapeutics Reports Promising Data for BEAM-302 in AATD Amidst Financial Challenges

April 5, 2025

Beam Therapeutics, a prominent player in the gene-editing sector, has released promising new data on its investigational therapy, BEAM-302, for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) at the 7th Global Research Conference and 10th Patient Congress organized by the Alpha-1 Foundation. The company reported that in the 60 mg cohort (n=3), the treatment led to a mean correction rate of 91% of total Alpha-1 Antitrypsin (AAT) in circulation by Day 28, showcasing the potential effectiveness of BEAM-302. BEAM-302 s Potential in AATD Treatment Alpha-1 Antitrypsin Deficiency is a genetic disorder that can lead to lung and liver disease. BEAM-302 is an experimental therapy using base editing to correct the genetic mutations responsible for AATD. The latest data demonstrated a significant promise, as the treatment achieved a high proportion of corrected M-AAT levels in the bloodstream of trial participants. These findings mark a pivotal step forward for BEAM-302, highlighting its potential as a transformative treatment for patients with AATD.

Promising Advances in Sickle Cell Disease Treatment Beam Therapeutics Unveils BEAM-101 Trial Data Amidst Financial Ch...

December 7, 2024

Beam Therapeutics Inc. has made significant strides in the treatment of sickle cell disease, presenting groundbreaking new data from its BEACON Phase 1/2 clinical trial of BEAM-101 during the recent American Society of Hematology (ASH) Annual Meeting. Notably, all seven patients who received BEAM-101 displayed remarkable results: a hemoglobin F (HbF) induction exceeding 60%, a reduction of hemoglobin S (HbS) to below 40%, and a resolution of anemia following treatment. These findings underscore the potential of BEAM-101 as a transformative therapy in managing this challenging genetic disorder.The results from the BEACON trial highlight the promising efficacy of BEAM-101, which employs advanced gene editing technology aimed at correcting the underlying genetic defect in hemoglobin production. The therapy s ability to induce significant levels of HbF is particularly noteworthy, given that elevated HbF levels can mitigate the symptoms and complications associated with sickle cell disease. As clinicians and researchers seek to improve patient outcomes in this field, the data presented at the ASH meeting may herald a new era in sickle cell treatment options.





Financial Statements
Beam Therapeutics Inc's II. Quarter Investments $ 1,305 Millions BEAM's Balance sheet
Beam Therapeutics Inc's II. Quarter Income $ -123 Millions Quarterly BEAM's Income Statement
BEAM's Income by Division See BEAM's Income by Division


BEAM Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 1,384 922 1,254 1,118 1,261
Y / Y Investment Growth 50.17 % -26.5 % 12.17 % -11.33 % 260.97 %
Net Income in Millions -80 -377 -133 -289 -371
Y / Y Net Income Growth - - - - -
Annual Return On Investment -5.78 % -40.87 % -10.57 % -25.85 % -29.39 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
BEAM's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for BEAM's Competitors
Subscribers only: Roi for Beam Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for BEAM's Customers

Other Ratios
BEAM's Roa BEAM's Inventory Turnover Ratio BEAM's Growth Rates BEAM's Dividend Statistics
BEAM's Profitability Ratios BEAM's Asset Turnover Ratio BEAM's Dividend Growth
BEAM's Roe BEAM's Valuation Ratios BEAM's Financial Strength Ratios BEAM's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:37:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.